Intralymphatic Immunotherapy (ILIT) Infographic
Summary
The infographic presents ILIT as a faster, lower-dose alternative to conventional subcutaneous immunotherapy (SCIT) for allergic disease.
- Traditional SCIT: 3-5 years of weekly or monthly injections, a high cumulative allergen dose, and delayed relief.
- ILIT: 3 ultra-low-dose injections over about 8-12 weeks, with claimed rapid and lasting relief and better adherence because of fewer visits.
- Procedure:
- An ultrasound locates a superficial lymph node (neck or groin).
- A micro-dose of allergen extract is injected into the node.
- Immune cells in the node encounter the allergen directly, building tolerance.
- Key messages: 3 injections give tolerance comparable to years of SCIT, lymph nodes act as “schools” for T-cells, and systemic risk is low.
Clinical Insights
Rationale
- Lymph nodes are where antigen-presenting cells, T-cells and B-cells meet. Direct delivery bypasses the inefficient, slow uptake from subcutaneous tissue.
- The original studies used roughly 1,000-fold less allergen than conventional SCIT. The proposed mechanisms are induction of regulatory T-cells, a shift toward Th1/IgG4 responses, and blunted IgE-mediated responses.
Evidence: promising but less settled than the infographic implies
- Early trials (Senti 2008, 2012) reported significant efficacy and tolerability after 3 injections for grass pollen and cat allergy.
- Later randomized trials are mixed. Some show clinical benefit (e.g., Hylander 2013 and Skaarup 2021). Others found limited or no significant advantage over placebo on key endpoints (e.g., Witten 2013 and Konradsen 2020).
- Heterogeneity is a major limitation: allergen extracts, doses, intervals (4-week vs. longer), number of injections and outcome measures all differ. Meta-analyses suggest benefit for allergic rhinitis, mainly in the short term, with low-to-moderate certainty.
- Long-term follow-up data (beyond about 3 years) are sparse, so “comparable to years of SCIT” is not yet established by head-to-head, long-term trials.
Safety
- Studies generally report mainly local, transient effects (injection-site or nodal swelling and discomfort). Systemic reactions have been uncommon, which supports the “low systemic risk” claim.
- “Excellent safety” is still a strong phrase. Anaphylaxis is a recognised risk of all allergen immunotherapy, and ILIT trials are small and mostly in carefully selected patients.
Practical and clinical considerations
- Indications studied: mainly IgE-mediated seasonal allergic rhinoconjunctivitis (grass, birch), plus smaller studies in cat and house dust mite allergy. Evidence for allergic asthma, food allergy and venom allergy is limited or experimental.
- Patient selection: confirmed sensitization (skin prick test or specific IgE) that matches symptoms. Standard immunotherapy precautions apply, including uncontrolled asthma, significant cardiovascular disease or beta-blocker use, and pregnancy considerations.
- Setting and operator skill: ultrasound-guided nodal puncture (inguinal nodes in most trials) requires training. Observation after injection and anaphylaxis readiness are essential.
- Regulatory status: ILIT is largely off-label and not yet endorsed as a standard of care. Major guidelines (e.g., EAACI) do not currently recommend it as routine therapy.
- Messaging: “The Future of Allergy Relief” and the “3 injections = years of SCIT” framing may overstate the evidence for patient-facing use. Consider adding “emerging therapy” and “under investigation” wording.
Key References
These are from memory. Please verify details such as volume and page numbers in PubMed before citing.
- Senti G, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA. 2008;105(46):17908-17912.
- Senti G, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129(5):1290-1296.
- Witten M, et al. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013;132(5):1248-1252.
- Hylander T, et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res. 2013;14:100.
- Patterson AM, et al. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2016;116(2):168-170.
- Hellkvist L, et al. Intralymphatic immunotherapy with 2 allergens (cat and birch) is safe and effective. J Allergy Clin Immunol. 2018;142(4):1338-1341.
- Konradsen JR, et al. Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: a randomized trial. J Allergy Clin Immunol. 2020;145(3):1005-1007.
- Skaarup SH, et al. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: a 3-year randomized placebo-controlled trial. J Allergy Clin Immunol. 2021;147(3):1011-1019.
- Hoang MP, et al. Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Rhinology. 2021;59(3):236-244.
- Roberts G, et al. EAACI guideline on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798.
- Dykewicz MS, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119(6):489-511.
HA Monotherapy vs. Combination Strategies — A Clinical Review for Aesthetic Practitioners